Literature DB >> 1107361

Rapid detoxification of the narcotic addict with naloxone hydrochloride. A preliminary report.

A A Kurland, L McCabe.   

Abstract

Parenteral (0.2--2.0 mg) and oral (500 mg) doses of naloxone hydrochloride were administered to 29 parolees showing evidence of increasing opiate use while participating in an aftercare abstinence program. The naloxone was found to be capable of inducing withdrawal symptoms, the intensity of which being a function of the amount of naloxone administered and of the level of physical dependence. Some patients (38%) showed a "detoxification effect" characterized by a positive abstinence reaction to initial naloxone administrations but a negative reaction to subsequent administrations. All of the 29 subjects, however, returned to illicit heroin use within several days following their release from the treatment unit. the potential of naloxone as a rapid detoxification tool is discussed in counterpoint to the apparent lack of potential the procedure has as a means of attenuating opiate-seeking behavior.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1107361     DOI: 10.1002/j.1552-4604.1976.tb01493.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

2.  Rapid opioid detoxification under general anesthesia.

Authors:  Masako Nishio; Clifford Mark Gevirtz
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

3.  Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice.

Authors:  H N Bhargava
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

4.  Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain.

Authors:  Elisabeth J Van Bockstaele; Yaping Qian; Robert C Sterling; Michelle E Page
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-03-25       Impact factor: 5.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.